Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2015

01.06.2015 | Original Article – Clinical Oncology

Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

verfasst von: Sung Hoon Sim, Yu Jung Kim, Se Hyun Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo, Jong Seok Lee

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Although about one-fourth of patients dying of lung cancer are aged 80 years or older in Korea, the current treatment status and outcome in octogenarians are largely unknown. We aimed to evaluate the proportion of octogenarians with advanced non-small cell lung cancer (NSCLC) who receive systemic chemotherapy and analyze the clinical outcome in these patients.

Methods

The medical records of 281 octogenarians who were diagnosed with stage IIIB/IV or recurrent NSCLC were retrospectively reviewed.

Results

In total, 127 out of 281 patients (45 %) received chemotherapy. Among the patients with ECOG PS 0–2, 119 patients (57 %) received chemotherapy. The first-line treatments were platinum doublets in 61 patients (48 %), single-agent chemotherapy in 34 (27 %), and epidermal growth factor receptor tyrosine kinase inhibitors in 32 (25 %). In patients with ECOG PS 0–2, patients who received chemotherapy lived longer compared with patients who only received best supportive care (16.1 vs. 4.0 months, P < 0.001). Among the 127 patients who received chemotherapy, patients who received EGFR TKIs showed longer survival than patients who only received cytotoxic agents (21.4 vs. 9.8 months, P < 0.001). In a multivariate analysis, ECOG PS 3–4 and smoking history were unfavorable prognostic factors, while recurrent disease and systemic chemotherapy were favorable prognostic factors.

Conclusion

Nearly half of octogenarians with advanced NSCLC received systemic chemotherapy. The patients showed prolonged survival compared with the best supportive care group. Further studies are warranted to provide an optimal tailored treatment for octogenarians.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, Zinner RG (2007) Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2(2):141–146PubMed Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, Zinner RG (2007) Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2(2):141–146PubMed
Zurück zum Zitat Asmis TR et al (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26:54–59. doi:10.1200/JCO.2007.12.8322 CrossRefPubMed Asmis TR et al (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26:54–59. doi:10.​1200/​JCO.​2007.​12.​8322 CrossRefPubMed
Zurück zum Zitat Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237CrossRefPubMed Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237CrossRefPubMed
Zurück zum Zitat Blanchard EM, Arnaoutakis K, Hesketh PJ (2010) Lung cancer in octogenarians. J Thorac Oncol 5:909–916CrossRefPubMed Blanchard EM, Arnaoutakis K, Hesketh PJ (2010) Lung cancer in octogenarians. J Thorac Oncol 5:909–916CrossRefPubMed
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
Zurück zum Zitat Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J (2003) A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 40:221–226CrossRefPubMed Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J (2003) A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 40:221–226CrossRefPubMed
Zurück zum Zitat Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Journal of the National Cancer Institute 91:66–72 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Journal of the National Cancer Institute 91:66–72
Zurück zum Zitat Ettinger DS et al (2013) Non-small cell lung cancer, version 2.2013. J Natl Compr Cancer Netw 11:645–653 quiz 653 Ettinger DS et al (2013) Non-small cell lung cancer, version 2.2013. J Natl Compr Cancer Netw 11:645–653 quiz 653
Zurück zum Zitat Frasci G et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536PubMed Frasci G et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536PubMed
Zurück zum Zitat Girones R, Torregrosa D, Gomez-Codina J, Maestu I, Tenias JM, Rosell R (2012) Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians. Clin Transl Oncol 14:183–189. doi:10.1007/s12094-012-0782-6 CrossRefPubMed Girones R, Torregrosa D, Gomez-Codina J, Maestu I, Tenias JM, Rosell R (2012) Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians. Clin Transl Oncol 14:183–189. doi:10.​1007/​s12094-012-0782-6 CrossRefPubMed
Zurück zum Zitat Gridelli C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372CrossRefPubMed Gridelli C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372CrossRefPubMed
Zurück zum Zitat Howlader N NA KM, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2014) SEER Cancer Statistics Review 1975–2011 National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site Howlader N NA KM, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2014) SEER Cancer Statistics Review 1975–2011 National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2011/​, based on November 2013 SEER data submission, posted to the SEER web site
Zurück zum Zitat Inoue A et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400. doi:10.1200/JCO.2008.18.7658 CrossRefPubMed Inoue A et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400. doi:10.​1200/​JCO.​2008.​18.​7658 CrossRefPubMed
Zurück zum Zitat Kudoh S et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657–3663. doi:10.1200/JCO.2006.06.1044 CrossRefPubMed Kudoh S et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657–3663. doi:10.​1200/​JCO.​2006.​06.​1044 CrossRefPubMed
Zurück zum Zitat Pallis AG et al. (2010) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 21:692-706 doi:10.1093/annonc/mdp360 Pallis AG et al. (2010) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 21:692-706 doi:10.​1093/​annonc/​mdp360
Zurück zum Zitat Pallis AG et al (2014) Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 25:1270–1283. doi:10.1093/annonc/mdu022 CrossRefPubMed Pallis AG et al (2014) Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 25:1270–1283. doi:10.​1093/​annonc/​mdu022 CrossRefPubMed
Zurück zum Zitat Quoix E et al (2011b) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079–1088. doi:10.1016/S0140-6736(11)60780-0 CrossRefPubMed Quoix E et al (2011b) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079–1088. doi:10.​1016/​S0140-6736(11)60780-0 CrossRefPubMed
Zurück zum Zitat Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed
Metadaten
Titel
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer
verfasst von
Sung Hoon Sim
Yu Jung Kim
Se Hyun Kim
Bhumsuk Keam
Tae Min Kim
Se-Hoon Lee
Dong-Wan Kim
Dae Seog Heo
Jong Seok Lee
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1875-0

Weitere Artikel der Ausgabe 6/2015

Journal of Cancer Research and Clinical Oncology 6/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.